Filing Flows › Halozyme Therapeutics (HALO) › Q2 2026 › vs Q1 2026
Halozyme Therapeutics (HALO) Q2 2026 vs Q1 2026 (quarter over quarter)
Halozyme Therapeutics's revenue rose $104M (+28%) from $377M in Q1 2026 to $481M in Q2 2026. Operating margin 59.8% against 49.0% (+10.8 pts).
Halozyme Therapeutics, Q2 2026: revenue $481M (+48% year over year), operating margin 59.8%, net earnings $230M, operating cash flow $241M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 59.8% | 49.0% | +10.8 pts |
| Net margin | 47.8% | 39.8% | +8.0 pts |
| Free cash flow margin | 49.2% | 46.8% | +2.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $481M | $377M | $104M | +28% |
| Operating profit | $288M | $185M | $103M | +56% |
| Costs & expenses | $193M | $192M | $1.2M | +0.6% |
| Pre-tax earnings | $285M | $180M | $105M | +58% |
| Other expense, net | $2.8M | $4.2M | −$1.4M | -34% |
| Cost of revenue | $79.2M | $79.2M | −$67K | -0.1% |
| Research & development | $27.7M | $25.6M | $2.1M | +8% |
| SG&A | $57.0M | $57.9M | −$883K | -2% |
| Other operating costs | $29.5M | $29.5M | $0 | 0% |
| Net earnings | $230M | $150M | $79.9M | +53% |
| Income tax | $55.0M | $30.3M | $24.7M | +82% |
| Depreciation & amortization | $4.5M | $4.2M | $279K | +7% |
| Share-based compensation | $17.7M | $16.6M | $1.1M | +6% |
| Working capital & other | $11.2M | −$9.2M | $20.4M | — |
| Operating cash flow | $241M | $180M | $60.8M | +34% |
| Free cash flow (OCF − capex) | $237M | $176M | $60.4M | +34% |
| Capital expenditures | $4.2M | $3.7M | $432K | +12% |
Questions
How much did Halozyme Therapeutics's revenue grow quarter over quarter in Q2 2026?
Halozyme Therapeutics's revenue rose $104M (+28%) from $377M in Q1 2026 to $481M in Q2 2026. Operating margin 59.8% against 49.0% (+10.8 pts).